Under the terms of the agreement, Sutro will provide its Xpress CF technology for the rapid and reproducible expression of antibodies and antigens by the Wells Lab for the comprehensive profiling of different target proteins and protein families in a high-throughput manner.
"RAN is a consortium of three highly integrated technology centers focused on the generation of high performance synthetic antibodies of tailored specificity," said Trevor Hallam, chief scientific officer of Sutro.
"Sutro’s Xpress CF technology allows for high-throughput screening and optimization of many different protein variants to quickly generate antibodies with the required specificity and characteristics. We are looking forward to working with Professor Wells and his team to design proteins and antibodies for a better understanding of cellular processes and for the advancement of medicinal chemistry."
Dr. Wells added, "High-quality antibodies that perform well and exhibit high affinity and specificity are not only very important therapeutics for many diseases, they are also essential for basic research. Technology that allows for parallel screening of many variants to generate quickly validated and renewable antibodies is an indispensable tool for researching the functions of specific proteins under normal or pathophysiological conditions."